Market Indices
Latest News
 |
| ||
| ||
| ||
|
Price Targets
Trevor Allred from Oppenheimer issued a price target of $145.00 for DNTH on 2026-03-09 14:15:00.The adjusted price target was set to $145.00.At the time of the announcement, DNTH...
March 9, 2026 DNTH 16.67%
Alex Thompson from Stifel Nicolaus issued a price target of $120.00 for DNTH on 2026-03-09 14:14:00.The adjusted price target was set to $120.00.At the time of the announcement,
March 9, 2026 DNTH 16.67%
Michael Shlisky from D.A. Davidson issued a price target of $23.00 for MEC on 2026-03-09 12:41:00.The adjusted price target was set to $23.00.At the time of the announcement,
March 9, 2026 MEC -1.43%
Andrew Tsai from Jefferies issued a price target of $10.00 for ATAI on 2026-03-06 20:37:00.The adjusted price target was set to $10.00.At the time of the announcement, ATAI...
March 6, 2026 ATAI 9.14%
Brian Holland from D.A. Davidson issued a price target of $24.00 for MAMA on 2026-03-06 13:50:00.The adjusted price target was set to $24.00.At the time of the announcement,
March 6, 2026 MAMA -2.82%
Market Movers
| Top Gainers (%) | |||||||||||||||||||
| EGRX Eagle Pharmaceuticals, In | 0.25
66.67% | ||||||||||||||||||
| ATRA Atara Biotherapeutics, In | 7.13
37.91% | ||||||||||||||||||
| CCCC C4 Therapeutics, Inc. | 3.75
23.19% | ||||||||||||||||||
| LTCH Latch, Inc. | 0.24
20.00% | ||||||||||||||||||
| BTAI BioXcel Therapeutics, Inc | 1.76
18.92% | ||||||||||||||||||
| DNTH Dianthus Therapeutics, In | 76.07
16.67% | ||||||||||||||||||
| SLDB Solid Biosciences Inc. | 7.84
16.07% | ||||||||||||||||||
| AXTI AXT, Inc. | 36.89
13.97% | ||||||||||||||||||
Annual/Quarterly Reports Summary
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
November 6, 2024 AIP -2.86%
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
November 6, 2024 EOSEW -34.96%
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
November 6, 2024 EOSE -3.54%
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
November 5, 2024 STOK 5.10%
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
November 5, 2024 BSVN -3.32%